Quale sarebbe il prezzo per MetaVia Inc. (MTVA)

Il prezzo per MetaVia Inc. (MTVA) è $1.51

Qual è la capitalizzazione di mercato per MetaVia Inc. (MTVA)

La capitalizzazione di mercato per MetaVia Inc. (MTVA) è $3.32M

MetaVia Inc. (MTVA) Dividendi

Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.

Anno	Dividendo (rettificato per split azionari)	Cambia
Non abbastanza dati per le date fornite.

Anno

Dividendo (rettificato per split azionari)

Cambia

Non abbastanza dati per le date fornite.

Anno	Dividendo	Cambia
Non abbastanza dati per le date fornite.

Anno

Dividendo

Cambia

Non abbastanza dati per le date fornite.

Azienda	Numero di pagamenti di dividendi	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	29.00%	BE

Azienda

Numero di pagamenti di dividendi

Il paese